Angion Biomedica Corp

Company Profile

Angion Biomedica Corp had its IPO on 2021-02-05 under the ticker symbol ANGN.

The company operates in the Healthcare sector and Biotechnology industry. Angion Biomedica Corp has a staff strength of 71 employees.

Stock update

Shares of Angion Biomedica Corp opened at $10.6 at the start of the last trading session i.e. 2023-06-02.

The stocks traded within a range of $8.9 - $10.6, and closed at $10.

This is a +2.04% increase from the previous day's closing price.

A total volume of 224,845 shares were traded at the close of the day’s session.

In the last one week, shares of Angion Biomedica Corp have increased by +19.23%.

Angion Biomedica Corp's Key Ratios

Angion Biomedica Corp has a market cap of $19.53 million, indicating a price to book ratio of 0.4859 and a price to sales ratio of 0.8958.

In the last 12-months Angion Biomedica Corp’s revenue was $28.24 million with a gross profit of $-20819000 and an EBITDA of $-11718000. The EBITDA ratio measures Angion Biomedica Corp's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Angion Biomedica Corp’s operating margin was -42.13% while its return on assets stood at -8.68% with a return of equity of -30.47%.

In Q3, Angion Biomedica Corp’s quarterly earnings growth was a positive 0% while revenue growth was a positive 20.9%.

Angion Biomedica Corp’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

Its diluted EPS in the last 12-months stands at $-0.49 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Angion Biomedica Corp’s profitability.

Angion Biomedica Corp stock is trading at a EV to sales ratio of 2.2573 and a EV to EBITDA ratio of 2.4526. Its price to sales ratio in the trailing 12-months stood at 0.8958.

Angion Biomedica Corp stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$61.32 million

Total Liabilities

$8.18 million

Operating Cash Flow

$0

Capital Expenditure

$0

Dividend Payout Ratio

0%

Angion Biomedica Corp ended 2023 with $61.32 million in total assets and $0 in total liabilities. Its intangible assets were valued at $61.32 million while shareholder equity stood at $50.21 million.

Angion Biomedica Corp ended 2023 with $0 in deferred long-term liabilities, $8.18 million in other current liabilities, 301000.00 in common stock, $-247502000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $55.14 million and cash and short-term investments were $55.14 million. The company’s total short-term debt was $1,032,000 while long-term debt stood at $0.

Angion Biomedica Corp’s total current assets stands at $56.68 million while long-term investments were $874000.00 and short-term investments were $0. Its net receivables were $7000.00 compared to accounts payable of $2.22 million and inventory worth $0.

In 2023, Angion Biomedica Corp's operating cash flow was $0 while its capital expenditure stood at $0.

Comparatively, Angion Biomedica Corp paid $0 in dividends in 2023.

Other key metrics

Current Trading Price

$10

52-Week High

$2.625

52-Week Low

$0.59

Analyst Target Price

$1.5

Angion Biomedica Corp stock is currently trading at $10 per share. It touched a 52-week high of $2.625 and a 52-week low of $2.625. Analysts tracking the stock have a 12-month average target price of $1.5.

Its 50-day moving average was $7.08 and 200-day moving average was $8.18 The short ratio stood at 0.68 indicating a short percent outstanding of 0%.

Around 3301.5% of the company’s stock are held by insiders while 1635.5% are held by institutions.